1
|
Yoshimura A, Nakakami A, Komaki R, Isogai A, Endo Y, Ozaki Y, Nozawa K, Kataoka A, Kotani H, Hattori M, Sawaki M, Iwata H. P289 Retrospective study of pregnancy outcome after breast cancer. Breast 2023. [DOI: 10.1016/s0960-9776(23)00407-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
2
|
Endo Y, Kotani H, Nakakami A, Komaki R, Isogai A, Ozaki Y, Nozawa K, Kataoka A, Yoshimura A, Hattori M, Sawaki M, Iwata H. P232 A study to evaluate the safety and utility of targeted axillary dissection using Guiding-Marker System. Breast 2023. [DOI: 10.1016/s0960-9776(23)00350-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
3
|
Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar L, Heymach J, Bonner J, Kuzma C, Waqar S, Petty W, Stinchcombe T, Bradley J, Vokes E. 1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Chun S, Liao Z, Jeter M, Chang J, Lin S, Komaki R, Guerrero T, Mayo R, Korah B, Koshy S, Heymach J, Koong A, Skinner H. P1.20 Metabolic Responses to Metformin in Early-Stage NSCLC Treated with Definitive Radiotherapy: Results of a Phase II Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Bogart J, Wang X, Masters G, Zhu H, Komaki R, Gaspar L, Dobelbower M, Kuzma C, Heymach J, Vokes E, Stinchcombe T. Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz264.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Stinchcombe T, Fan W, Schild S, Vokes E, Bogart J, Le QT, Thomas C, Edelman M, Horn L, Komaki R, Cohen H, Ganti A, Pang H, Wang X. A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy298.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Videtic G, Paulus R, Singh A, Chang J, Parker W, Olivier K, Timmerman R, Komaki R, Urbanic J, Stephans K, Yom S, Robinson C, Belani C, Iyengar P, Ajlouni M, Gopaul D, Lele S, Mcgarry R, Choy H, Bradley J. MA 13.08 Long Term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a Randomized Phase II Study of 2 SBRT Schedules for Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Komaki R. PC 02.01 Thoracic Radiation - YES. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Komaki R, Oda T, Takata M, Endo H, Hosomi M, Hamaguchi H. Frailty and malnutrition predict poor outcomes in acute ischemic stroke patients. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2456] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Komaki R. Targeted Treatment for the Non- Small Cell Lung Cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)30122-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
11
|
Lin S, Zhang N, Godby J, Wang J, Marsh G, Liao Z, Komaki R, Ho L, Hofstetter W, Swisher S, Mehran R, Buchholz T, Elting L, Giordano S. OC-0124: IMRT or 3DCRT and cardiopulmonary mortality risk in the elderly with Eeophageal cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40122-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Lustberg T, Bailey M, Thwaites D, Miller A, Carolan M, Holloway L, Rios E, Dekker A, Hoebers F, Harris J, Dignam J, Komaki R, Trotti A, De los Santos J, McGarry R, Galloway T, Michalski J. PD-0422: Validating a 2 year survival prediction model for laryngeal carcinoma patients in a clinical care and trial setting. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40418-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Zhou R, Scheurer M, Vera-Bolanos E, Gilbert M, Bondy M, Sulman E, Hilsenbeck S, Wendland M, Brachman D, Roof K, Komaki R, Deutsch M, Andrews D, Anderson B, Lee RJ, Pugh S, Armstrong T. CN-21 * RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou243.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Thaker N, Komaki R, Golden D, Boehling N, Gunther J, Hillebrandt E, Mahajan A, Cox J, Frank S, Woodward W, Das P. Improving the Quality of Radiation Oncology Education Through an Innovative Medical Student Treatment Planning Curriculum. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Furutani S, Komaki R, Smith P, Jürgensmeier J, Takahashi O, Rabin T, Herbst R, O'Reilly M. MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
16
|
Liu A, Xu T, Gomez D, O'Reilly M, Lin S, Nguyen Q, Levy L, Komaki R, Mohan R, Liao Z. Serum CRP Is Predictive if Survival in Non-Small-Cell Lung Cancer Patients Treated With Definitive Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Nguyen Q, Komaki R, Liao Z, Ly N, Levy L, Gomez D, Chang J, Cox J. The 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Xu T, Gomez D, O'Reilly M, Nguyen Q, Levy L, Komaki R, Mohan R, Liao Z. Serum VEGF Associated With Survival in Non-Small Cell Lung Cancer Patients Treated With Definitive Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Farnia B, Lin S, Tang C, Allen P, Liao Z, Chang J, Welsh J, Komaki R, Mehran R, Gomez D. Conformal Fields in Postoperative Radiation Therapy for NSCLC Are Not Associated With High Rates of Regional Nodal Recurrence. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
20
|
Pu X, Wang L, Chang JY, Hildebrandt MAT, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther 2014; 96:609-15. [PMID: 25054431 PMCID: PMC4206576 DOI: 10.1038/clpt.2014.154] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 07/16/2014] [Indexed: 12/25/2022]
Abstract
Definitive radiotherapy improves locoregional control and survival in inoperable non-small cell lung cancer (NSCLC) patients. However, radiation-induced toxicities (pneumonitis/esophagitis) are common dose-limiting inflammatory conditions. We therefore conducted a pathway-based analysis to identify inflammation-related SNPs associated with radiation-induced pneumonitis or esophagitis. 11,930 SNPs were genotyped in 201 stage I-III NSCLC patients treated with definitive radiotherapy. Validation was performed in an additional 220 NSCLC cases. After validation, 19 SNPs remained significant. A polygenic risk score (PRS) was generated to summarize the effect from validated SNPs. Significant improvements in discriminative ability were observed by adding the PRS into the clinical/epidemiological variable-based model. We then used 277 lymphoblastoid cell-lines to assess radiation sensitivity and eQTL relationships of the identified SNPs. Three genes (PRKCE,DDX58 and TNFSF7) were associated with radiation sensitivity. We concluded that inflammation-related genetic variants could contribute to the development of radiation-induced toxicities. These loci could assist in predicting those unfavorable events.
Collapse
Affiliation(s)
- X Pu
- Department of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - L Wang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
| | - J Y Chang
- Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - M A T Hildebrandt
- Department of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Y Ye
- Department of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - C Lu
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - H D Skinner
- Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - N Niu
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
| | - G D Jenkins
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
| | - R Komaki
- Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - J D Minna
- Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - J A Roth
- Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - R M Weinshilboum
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
| | - X Wu
- Department of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
21
|
Francis A, Correa A, Betancourt-Cuellar S, Kim J, Sepesi B, Ajani J, Komaki R, Erasmus J, Maru D, Mehran R, Rice D, Roth J, Vaporciyan A, Walsh G, Hofstetter W, Swisher S. Esophageal Tumor Thickness on Computed Tomography as a Predictor of Residual Tumor in Esophageal Adenocarcinoma Following Preoperative Chemoradiation. J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Komaki R, Kim Y, Wistuba I, Tang X, Meyn R, Allen P, Wei X, Lee I, O’Reilly M, Blumenschein G, Hong W. 104: Vimentin (EMT Marker Protein) Score As One of Predictors Resistance to Erlotinib and Radiotherapy for Patients with Stage III Non-Small Cell Lung Cancer on A Prospective Phase II Trial. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)34125-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol 2013; 8:142-9. [PMID: 24210755 DOI: 10.1016/j.molonc.2013.10.007] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Revised: 10/14/2013] [Accepted: 10/15/2013] [Indexed: 01/16/2023] Open
Abstract
PURPOSE Operable thoracic esophageal/gastroesophageal junction carcinoma (EC) is often treated with chemoradiation and surgery but tumor responses are unpredictable and heterogeneous. We hypothesized that aldehyde dehydrogenase-1 (ALDH-1) could be associated with response. METHODS The labeling indices (LIs) of ALDH-1 by immunohistochemistry in untreated tumor specimens were established in EC patients who had chemoradiation and surgery. Univariate logistic regression and 3-fold cross validation were carried out for the training (67% of patients) and validation (33%) sets. Non-clinical experiments in EC cells were performed to generate complimentary data. RESULTS Of 167 EC patients analyzed, 40 (24%) had a pathologic complete response (pathCR) and 27 (16%) had an extremely resistant (exCRTR) cancer. The median ALDH-1 LI was 0.2 (range, 0.01-0.85). There was a significant association between pathCR and low ALDH-1 LI (p ≤ 0.001; odds-ratio [OR] = 0.432). The 3-fold cross validation led to a concordance index (C-index) of 0.798 for the fitted model. There was a significant association between exCRTR and high ALDH-1 LI (p ≤ 0.001; OR = 3.782). The 3-fold cross validation led to the C-index of 0.960 for the fitted model. In several cell lines, higher ALDH-1 LIs correlated with resistant/aggressive phenotype. Cells with induced chemotherapy resistance upregulated ALDH-1 and resistance conferring genes (SOX9 and YAP1). Sorted ALDH-1+ cells were more resistant and had an aggressive phenotype in tumor spheres than ALDH-1- cells. CONCLUSIONS Our clinical and non-clinical data demonstrate that ALDH-1 LIs are predictive of response to therapy and further research could lead to individualized therapeutic strategies and novel therapeutic targets for EC patients.
Collapse
Affiliation(s)
- J A Ajani
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA.
| | - X Wang
- Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - S Song
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - A Suzuki
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - T Taketa
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - K Sudo
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - R Wadhwa
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - W L Hofstetter
- Department of Cardiac and Thoracic Surgery, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - R Komaki
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - D M Maru
- Department of Pathology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - J H Lee
- Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - M S Bhutani
- Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - B Weston
- Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - V Baladandayuthapani
- Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - Y Yao
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - S Honjo
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - A W Scott
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - H D Skinner
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - R L Johnson
- Department of Genetics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - D Berry
- Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| |
Collapse
|
24
|
Rengan R, Ho A, Owen JB, Komaki R, Khalid N, Wilson JF, Movsas B. Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology survey. Pract Radiat Oncol 2013; 4:e167-e179. [PMID: 24766691 DOI: 10.1016/j.prro.2013.07.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 07/05/2013] [Accepted: 07/16/2013] [Indexed: 11/30/2022]
Abstract
PURPOSE The objective of this study is to describe the impact of sociodemographic (SOC) factors on the management of lung cancer patients treated at radiation therapy facilities participating in the Quality Research in Radiation Oncology survey. METHODS AND MATERIALS A 2-stage stratified random sample of lung cancer patients treated in 2006 to 2007 at 45 facilities yielded 340 stage I-III non-small cell lung cancer (NSCLC) and 144 limited-stage small cell lung cancer (LS-SCLC) cases. Five SOC variables based on data from the 2000 US Census were analyzed for association with the following clinical factors: patients living in urban versus rural settings (U/R); median household income (AHI); % below poverty level (PPV); % unemployed (PUE); and % with college education (PCE). RESULTS The 340 NSCLC patients were stage I, 16%; stage II, 11%; stage III, 62%; stage unknown, 11%. Histologic subtypes were adenocarcinoma, 31.8%; squamous cell carcinoma, 35.3%; large cell carcinoma, 3.2%; and NSCLC NOS, 27.7%. The median age was 66 years. Median Karnofsky performance status (KPS) was 80. The 144 LS-SCLC had a median age of 63; 73 were male (50.7%). Median KPS was 80. Stereotactic body radiation therapy (SBRT) and modern imaging utilization was associated with treatment at facilities located in higher SOC regions. SBRT was employed in 46.8% stage I NSCLC patients treated in centers where %PUE was below median versus 14.8% in centers where %PUE was above median (P = .02). Four-dimensional computed tomography was utilized in 14.2% of patients treated in centers located in regions with %PPV below median versus 3.7% in centers located in regions with %PPV above median (P < .01). SCLC patients were more likely to receive all of their planned RT when treated at centers located in regions with lower PPV (95.0% vs 79.1%; P = .04). CONCLUSIONS SOC factors may impact use of modern treatment planning and delivery and multidisciplinary management of NSCLC and SCLC. These results may suggest an impact of these SOC factors on access to health care.
Collapse
Affiliation(s)
- Ramesh Rengan
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
| | - Alex Ho
- American College of Radiology, Philadelphia, PA
| | - Jean B Owen
- American College of Radiology, Philadelphia, PA
| | - R Komaki
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Benjamin Movsas
- Department of Radiation Oncology, Henry Ford Hospital, Dearborn, MI
| |
Collapse
|
25
|
Videtic G, Hu C, Singh A, Chang J, Parker W, Olivier K, Schild S, Komaki R, Urbanic J, Choy H. Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.016] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
26
|
Lin S, Gao H, Wei C, Marrinucci D, Nelson D, Liao Z, Komaki R, Hauch S, Kuhn P, Reuben J. Circulating Tumor Cells With Markers of Epithelial-Mesenchymal Transition Are Associated With Distant Metastatic Failures in Lung Cancer Patients Treated With Definitive Chemoradiation. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Xu T, Gomez D, O'Reilly M, Guerrero T, Nguyen Q, Levy L, Huo J, Komaki R, Mohan R, Liao Z. Serum TGF-β1 and VEGF Are Associated With Tumor Burden and Tumor Response on PET to (Chemo)radiation Therapy in Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Chang J, Xu Q, Balter P, James W, Gomez D, Komaki R, Roth J, Swisher S. Clinical Outcome and Toxicity in Central Located Stage I or Isolated Recurrent Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1361] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
29
|
Xu T, Gomez D, O'Reilly M, Levy L, Welsh J, Lin S, Komaki R, Liu Z, Wei Q, Liao Z. Circulating miR-155 Predicts for Acute Esophageal Toxicity in Patients With Non-Small Cell Lung Cancer Treated With Radiation Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Wang J, Lin S, Allen P, Juloori A, Lee J, Komaki R, Liao Z, Swisher S, Hofstetter W, Ajani J. Nomogram Score of Pathologic Complete Response to Neoadjuvant Chemoradiation Predicts for Survival Outcomes in Esophageal Cancer Patients Treated With Definitive Chemoradiation. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Juloori A, Tucker S, Lee J, Myles B, Palmer M, Komaki R, Liao Z, Lin S. Dosimetric Predictors for Nausea and Anorexia in Esophageal Cancer Patients Treated With Neoadjuvant Chemoradiation. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Naik N, Swanick C, Wei C, Liao Z, Welsh J, Komaki R, Chang J, O'Reilly M, Gomez D, Lin S. High Local Failure Rates Despite Dose Escalation May Support the Metastatic Self-Seeding Phenomenon in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Grant J, Sobremonte A, Hillebrandt E, Allen P, Lin S, Chang J, Komaki R, Liao Z, Heymach J, Gomez D. Dosimetric Impact of Induction Chemotherapy on Subsequent Radiation Treatment Planning in Patients With Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Wei X, Allen P, Gomez D, Kotamarti K, Heymach J, Welsh J, O'Reilly M, Lin S, Cox J, Komaki R. Improved 5-Year Disease Free-Survival and Distant Metastasis-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer Who Had 18F-fluorodeoxyglucose Positron Emission Tomography (PET) or PET/CT Before Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Evans J, Gomez D, Chang J, Gladish G, Erasmus J, Rebueno N, Banchs J, Komaki R, Welsh J. Cardiac Isodose Distributions and Increases in Focal 18F-Fluorodeoxyglucose Uptake on Positron Emission Tomography After Thoracic Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Lin S, Zhang J, Giri U, Stephan C, Sobieski M, Nguyen N, Davies P, Komaki R, Yoo S, Heymach J. High Throughput Clonogenic Survival Screen Identifies Novel Radiation Sensitizers for K-ras Mutant Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1723] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol 2013; 24:2854-9. [PMID: 23994746 DOI: 10.1093/annonc/mdt340] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Patients with localized esophageal adenocarcinoma (EAC) who achieve a clinical complete response (clinCR) after preoperative chemoradiation (trimodality therapy; TMT) or definitive chemoradiation (bimodality therapy; BMT) live longer than those who achieve a <clinCR (Suzuki A, Xiao LC, Hayashi Y et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011; 117: 4823-4833; Cheedella NK, Suzuki A, Xiao L et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 2013; 24: 1262-1266; Ajani JA, Correa AM, Hofstetter WL et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012; 23: 2638-2642). We hypothesized that the initial standardized uptake value (iSUV) of positron emission tomography will define novel subsets of clinCR patients. METHODS We analyzed 323 EAC patients, from our prospective database, who achieved a clinCR. Various statistical methods were used to assess the influence of iSUV on patient outcome. RESULTS The median follow-up of 323 patients was 40.8 months [95% confidence interval (CI) 35.6-47.3 months]. Two hundred six (63.8%) patients had TMT and 117 (36.2%) had BMT. If iSUV was ≥6, TMT patients had a longer median OS (94.8 months; 95% CI 66.07-NA) than BMT patients (31.4 months; 95% CI 21.7-42.1; P ≤ 0.001). However, if iSUV was <6, the median OS of TMT and BMT patients was similar (P = 0.62). iSVU did not influence the pathologic complete response rate in TMT patients (P = 0.85). CONCLUSION clinCR patients with iSUV of <6 are identified as a new subset that fared equally well when treated with TMT or BMT. Future esophageal preservation strategy may be best suited for this newly identified subset of EAC patients.
Collapse
Affiliation(s)
- A Suzuki
- Department of Gastrointestinal Medical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2013; 24:2844-9. [PMID: 23975663 DOI: 10.1093/annonc/mdt339] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The contribution of induction chemotherapy (IC) before preoperative chemoradiation for esophageal cancer (EC) is not known. We hypothesized that IC would increase the rate of pathologic complete response (pathCR). METHODS Trimodality-eligibile patients were randomized to receive no IC (Arm A) or IC (oxaliplatin/FU; Arm B) before oxaliplatin/FU/radiation. Surgery was attempted ∼5-6 weeks after chemoradiation. The pathCR rate, post-surgery 30-day mortality, overall survival (OS), and toxic effects were assessed. Bayesian methods and Fisher's exact test were used. RESULTS One hundred twenty-six patients were randomized dynamically to balance the two arms for histology, baseline stage, gender, race, and age. Fifty-five patients in Arm A and 54 in Arm B underwent surgery. The median actuarial OS for all patients (54 deaths) was 45.62 months [95% confidence interval (CI), 27.63-NA], with median OS 45.62 months (95% CI 25.56-NA) in Arm A and 43.68 months (95% CI 27.63-NA) in Arm B (P = 0.69). The pathCR rate in Arm A was 13% (7 of 55) and 26% (14 of 54) in Arm B (two-sided Fisher's exact test, P = 0.094). Safety was similar in both arms. CONCLUSIONS These data suggest that IC produces non-significant increase in the pathCR rate and does not prolong OS. Further development of IC before chemoradiation may not be beneficial. Clinical trial no.: NCT 00525915 (www.clinicaltrials.gov).
Collapse
Affiliation(s)
- J A Ajani
- Departments of Gastrointestinal Medical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 2013; 24:1312-9. [PMID: 23300016 DOI: 10.1093/annonc/mds616] [Citation(s) in RCA: 149] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Preclinical studies have shown that norepinephrine can directly stimulate tumor cell migration and that this effect is mediated by the beta-adrenergic receptor. PATIENTS AND METHODS We retrospectively reviewed 722 patients with non-small-cell lung cancer (NSCLC) who received definitive radiotherapy (RT). A Cox proportional hazard model was utilized to determine the association between beta-blocker intake and locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). RESULTS In univariate analysis, patients taking beta-blockers (n = 155) had improved DMFS (P < 0.01), DFS (P < 0.01), and OS (P = 0.01), but not LRPFS (P = 0.33) compared with patients not taking beta-blockers (n = 567). In multivariate analysis, beta-blocker intake was associated with a significantly better DMFS [hazard ratio (HR), 0.67; P = 0.01], DFS (HR, 0.74; P = 0.02), and OS (HR, 0.78; P = 0.02) with adjustment for age, Karnofsky performance score, stage, histology type, concurrent chemotherapy, radiation dose, gross tumor volume, hypertension, chronic obstructive pulmonary disease and the use of aspirin. There was no association of beta-blocker use with LRPFS (HR = 0.91, P = 0.63). CONCLUSION Beta-blocker use is associated with improved DMFS, DFS, and OS in this large cohort of NSCLC patients. Future prospective trials can validate these retrospective findings and determine whether the length and timing of beta-blocker use influence survival outcomes.
Collapse
Affiliation(s)
- H M Wang
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 2013; 24:67-74. [PMID: 23002278 PMCID: PMC3525136 DOI: 10.1093/annonc/mds274] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Revised: 06/14/2012] [Accepted: 06/20/2012] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND The purpose of this study was to evaluate the actuarial risk of local and regional failure in patients with completely resected non-small-cell lung cancer (NSCLC), and to assess surgical and pathological factors affecting this risk. PATIENTS AND METHODS Between January 1998 and December 2009, 1402 consecutive stage I-III (N0-N1) NSCLC patients underwent complete resection without adjuvant radiation therapy. The median follow-up was 42 months. RESULTS Local-regional recurrence was identified in 9% of patients, with local failure alone in 3% of patients, regional failure alone in 4% of patients, and both local and regional failure simultaneously in 2% of patients. Patients who had local failure were found to be at increased risk of mortality. By multivariate analyses, three variables were shown to be independently significant risk factors for local [surgical procedure (single/multiple wedges+segmentectomy versus lobectomy+bilobectomy+pneumonectomy), tumor size>2.7 cm, and visceral pleural invasion] and regional (pathologic N1 stage, visceral pleural invasion, and lymphovascular space invasion, LVI) recurrence, respectively. CONCLUSION Patients with N0-N1 disease have low rates of locoregional recurrence after surgical resection. However, several prognostic factors can be identified that increase this risk and identify patients who may benefit from adjuvant treatment.
Collapse
Affiliation(s)
- J. L. Lopez Guerra
- Departments ofRadiation Oncology
- Department of Radiation Oncology, Instituto Madrileño de Oncologia/Grupo IMO, Madrid, Spain
| | | | | | | | | | | | - J. Jaen
- Department of Radiation Oncology, Instituto Madrileño de Oncologia/Grupo IMO, Madrid, Spain
| | - A. A. Vaporciyan
- Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S. G. Swisher
- Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
| | | | - Z. Liao
- Departments ofRadiation Oncology
| | - D. C. Rice
- Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
| |
Collapse
|
41
|
Zhuang Y, Gomez D, Komaki R, O'Reilly M, Welsh J, Lin S, Chang J, Jeter M, Liao Z. Prognostic Factors for Overall Survival in Stage IIIA/IIIB Non-small Cell Lung Cancer After Definitive (Chemo)radiation Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Grant J, Gomez D, Zhuang Y, Chang J, Komaki R, Fossella F, Gold K, Liao Z, Cox J. Impact of Chemotherapy Response and Radiation Dose on Overall Survival in Patients With Inoperable Non-small Cell Lung Cancer Treated With Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
McAvoy S, Komaki R, Allen P, Rineer J, Liao Z, Chang J, Welsh J, Palmer M, Cox J, Gomez D. Reirradiation With Proton Beam Therapy or Intensity Modulated Radiation Therapy for Non-small Cell Lung Cancer: An Institutional Experience. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
44
|
Welsh J, Likacheva A, Byers L, Bhardwaj V, Diao L, Wang J, Ang K, Komaki R, Kim E, Heymach J. Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Mohan R, Matney J, Bluett J, Palmer M, Choi N, Chang J, Komaki R, Cox J, Liao Z. IMRT Versus Passively Scattered Proton Therapy (PSPT) for Locally Advanced NSCLC -- Impact of Changing Techniques and Technologies Over the Course of a Randomized Trial. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1506] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Wang H, Gomez D, Komaki R, Welsh J, O'Reilly M, Chang J, Zhuang Y, Levy L, Lu C, Liao Z. Improved Survival Outcomes in Non-small Cell Lung Cancer Patients With Incidental Concurrent Use of Beta-Blockers and Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Fakhreddine M, Liao Z, Zhuang Y, Bhardwaj V, Tucker S, Skinner H, Heymach J, Gomez D, Komaki R, Welsh J. Poor Glycemic Control During Radiochemotherapy Contributes to Reduced Local Control and Overall Survival in Patients With Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Shirvani S, Juloori A, Gomez D, Allen P, Komaki R, O'Reilly M, Liao Z, Welsh J, Papadimitrakopoulou V, Chang J. Patterns of Failure for Limited-Stage Small Cell Lung Cancer Following Definitive Radiation Therapy in the Modern Era. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012; 23:2638-2642. [PMID: 22831985 DOI: 10.1093/annonc/mds210] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Approximately 25% of patients with esophageal cancer (EC) who undergo preoperative chemoradiation, achieve a pathologic complete response (pathCR). We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability. PATIENTS AND METHODS We analyzed 322 patients with EC who underwent preoperative chemoradiation. All the patients had baseline and postchemoradiation positron emission tomography (PET) and pre- and postchemoradiation endoscopic biopsy. Logistic regression models were used for analysis, and cross-validation via the bootstrap method was carried out to test the model. RESULTS The 70 (21.7%) patients who achieved a pathCR lived longer (median overall survival [OS], 79.76 months) than the 252 patients who did not achieve a pathCR (median OS, 39.73 months; OS, P = 0.004; disease-free survival, P = 0.003). In a logistic regression analysis, the following parameters contributed to the prediction model: postchemoradiation PET, postchemoradiation biopsy, sex, histologic tumor grade, and baseline (EUS)T stage. The area under the receiver-operating characteristic curve was 0.72 (95% confidence interval [CI] 0.662-0.787); after the bootstrap validation with 200 repetitions, the bias-corrected AU-ROC was 0.70 (95% CI 0.643-0.728). CONCLUSION Our data suggest that the logistic regression model can predict pathCR with a high probability. This clinical model could complement others (biomarkers) to predict pathCR.
Collapse
Affiliation(s)
- J A Ajani
- Departments of Gastrointestinal Medical Oncology, Houston, USA.
| | - A M Correa
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - W L Hofstetter
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - D C Rice
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - M A Blum
- Departments of Gastrointestinal Medical Oncology, Houston, USA
| | - A Suzuki
- Departments of Gastrointestinal Medical Oncology, Houston, USA
| | - T Taketa
- Departments of Gastrointestinal Medical Oncology, Houston, USA
| | - J Welsh
- Departments of Radiation Oncology, Houston, USA
| | - S H Lin
- Departments of Radiation Oncology, Houston, USA
| | - J H Lee
- Departments of Gastroenterology, Hepatology, and Nutrition, Houston, USA
| | - M S Bhutani
- Departments of Gastroenterology, Hepatology, and Nutrition, Houston, USA
| | - W A Ross
- Departments of Gastroenterology, Hepatology, and Nutrition, Houston, USA
| | - D M Maru
- Departments of Pathology, Houston, USA
| | | | - J Erasmus
- Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R Komaki
- Departments of Radiation Oncology, Houston, USA
| | - R J Mehran
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - A A Vaporciyan
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - S G Swisher
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| |
Collapse
|
50
|
Gomez D, Guerra JL, Zhuang Y, Hong D, Heymach J, Swisher S, Lin S, Komaki R, Cox J, Liao Z. OC-0499 PROGNOSTIC IMPACT OF RADIATION THERAPY TO THE PRIMARY TUMOR IN PATIENTS WITH OLIGOMETASTATIC LUNG CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70838-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|